The US Food and Drug Administration (FDA) has accepted Sanofi’s Stage 3 Type 1 diabetes drug, Tzield, for expedited review. Tzield delays the progression of Stage 3 Type 1 diabetes (T1D) in patients eight years or older who have recently been diagnosed. Sanofi’s drug received expedited review as one of the recipients of the FDA’s […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
